secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2026-09-09T12:30:16+00:00
Accession:  0001493152-26-041894
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity regains Nasdaq compliance; hearing cancelled, listing continues
---------------------------------------------------------------------------

- Regained compliance with Nasdaq Minimum Bid Price Rule 5550(a)(2) and Rights/Warrants Rule 5560(a) as of Sept 8, 2026.
- Previously scheduled Nasdaq Hearings Panel hearing cancelled; BIAF and BIAFW continue trading on Nasdaq Capital Market.
- As of Sept 8, 2026: 1,166,625 shares outstanding; aggregate market value ~$10.4M based on closing price.
- Staff Determination on July 30, 2026 cited bid price below $1.00 for 30 consecutive days; appeal filed Aug 6, 2026.
- CEO Maria Zannes: pleased to regain compliance, focus on CyPath Lung test and pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226041894/0001493152-26-041894-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226041894/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-041894

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer